Below are the most recent publications written about "Anilides" by people in Profiles.
-
Nakazawa S, Pecci F, Odintsov I, Gazgalis D, Gottlieb FH, Ricciuti B, Zullo L, Alessi JV, Di Federico A, Aldea M, Garbo E, Gandhi MM, Saini A, Feng WW, Jiang J, Baldacci S, Facchinetti F, Makarem M, Locquet MA, Haratani K, Haradon D, Besse B, Italiano A, Remon J, Lavaud P, Vasseur D, Planchard D, Sato Y, Watanabe Y, Owen S, Cortot AB, Mahran H, Forster MD, Niu J, Tomasini P, Leong SS, Tay K, Esteban E, Minchom A, Kizilbash SH, Cruz-Correa M, Yu KP, Zhang X, Chen P, Sangem M, Che J, Sholl LM, J?nne PA, Awad MM. Antitumor Activity of Vebreltinib and Characterization of Clinicogenomic Features in Solid Tumors with MET Rearrangements. Cancer Discov. 2025 Jun 03; 15(6):1129-1140.
-
Chan JA, Geyer S, Zemla T, Knopp MV, Behr S, Pulsipher S, Ou FS, Dueck AC, Acoba J, Shergill A, Wolin EM, Halfdanarson TR, Konda B, Trikalinos NA, Tawfik B, Raj N, Shaheen S, Vijayvergia N, Dasari A, Strosberg JR, Kohn EC, Kulke MH, O'Reilly EM, Meyerhardt JA. Phase 3 Trial of Cabozantinib to Treat Advanced Neuroendocrine Tumors. N Engl J Med. 2025 Feb 13; 392(7):653-665.
-
Vukmanovic Nosrat I, Palacios JL, Kezian S, Luong G, Tran A, Vu K, Henson BS, Nosrat P, Lutfy K, Nosrat CA. Brain-derived neurotrophic factor overexpression in taste buds diminishes chemotherapy induced taste loss. Eur J Neurosci. 2022 10; 56(7):4967-4982.
-
Moscarella E, Brancaccio G, Briatico G, Ronchi A, Verolino P, Argenziano G, Alfano R. Management of advanced basal cell carcinoma: Real-life data with sonidegib. Dermatol Ther. 2021 05; 34(3):e14948.
-
Da Silva T, Hafizi S, Rusjan PM, Houle S, Wilson AA, Prce I, Sailasuta N, Mizrahi R. GABA levels and TSPO expression in people at clinical high risk for psychosis and healthy volunteers: a PET-MRS study. J Psychiatry Neurosci. 2019 03 01; 44(2):111-119.
-
Hafizi S, Da Silva T, Meyer JH, Kiang M, Houle S, Remington G, Prce I, Wilson AA, Rusjan PM, Sailasuta N, Mizrahi R. Interaction between TSPO-a neuroimmune marker-and redox status in clinical high risk for psychosis: a PET-MRS study. Neuropsychopharmacology. 2018 07; 43(8):1700-1705.
-
Joshi JB, Patel D, Morton DJ, Sharma P, Zou J, Hewa Bostanthirige D, Gorantla Y, Nagappan P, Komaragiri SK, Sivils JC, Xie H, Palaniappan R, Wang G, Cox MB, Chaudhary J. Inactivation of ID4 promotes a CRPC phenotype with constitutive AR activation through FKBP52. Mol Oncol. 2017 04; 11(4):337-357.
-
Flores JJ, Klebe D, Rolland WB, Lekic T, Krafft PR, Zhang JH. PPAR?-induced upregulation of CD36 enhances hematoma resolution and attenuates long-term neurological deficits after germinal matrix hemorrhage in neonatal rats. Neurobiol Dis. 2016 Mar; 87:124-33.
-
Liang S, Bian X, Liang D, Sivils JC, Neckers LM, Cox MB, Xie H. Solution formulation development and efficacy of MJC13 in a preclinical model of castration-resistant prostate cancer. Pharm Dev Technol. 2016; 21(1):121-6.
-
Ramachandran L, Manu KA, Shanmugam MK, Li F, Siveen KS, Vali S, Kapoor S, Abbasi T, Surana R, Smoot DT, Ashktorab H, Tan P, Ahn KS, Yap CW, Kumar AP, Sethi G. Isorhamnetin inhibits proliferation and invasion and induces apoptosis through the modulation of peroxisome proliferator-activated receptor ? activation pathway in gastric cancer. J Biol Chem. 2012 Nov 02; 287(45):38028-40.